| Bioactivity | Hyp9 is a transient receptor potential canonical 6 (TRPC6)-specific agonist. Hyp9 can be used for the research of spinal cord injury (SCI)[1]. |
| Invitro | HYP9 (0, 1, 5, 10, 15, 20, 25, 30 µM; 72 h) 以剂量依赖性方式抑制星形胶质细胞增殖[1]。HYP9 显著抑制 AP4 过表达[1]。 Cell Proliferation Assay[1] Cell Line: |
| In Vivo | HP9（鞘内注射；5 μg；1、3、5 和 7 天）通过抑制 SCl 大鼠体内模型中的 AQP4 来抑制星形胶质细胞的活化和增殖，并在 SCI 后保持神经元存活和功能恢复[1]。 Animal Model: |
| Name | Hyp9 |
| CAS | 3118-34-1 |
| Formula | C18H26O5 |
| Molar Mass | 322.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jiajun Cai, et al. Upregulation of TRPC6 inhibits astrocyte activation and proliferation after spinal cord injury in rats by suppressing AQP4 expression. Brain Res Bull. 2022 Nov;190:12-21. |